EGFR and cancer: According to Amelia et al.’s report [5], mutated EGFR results in the constant activation of the tyrosine kinase domain, which in turn promotes the growth, proliferation, invasion, and metastasis of cancer cells without the presence of ligands, making it an essential oncogenic driver and target point for cancer therapy [6].